Neonatal screening for sickle cell disease, caveats about potential cure with innovative medical technology and the relevant evidence-based health education Online publication date: Tue, 28-Jan-2014
by E. William Ebomoyi
International Journal of Medical Engineering and Informatics (IJMEI), Vol. 5, No. 1, 2013
Abstract: This project assessed the techniques for neonatal screening and the clinical management of sickle cell disease (SCD). Caution about bone marrow transplant (BMT) and gene therapy (GT) was provided. The global distribution of SCD was illustrated. The agonising pain associated with the signs and symptoms of SCD were analysed as the rationale for adoption of bone marrow transplant and gene therapy to cure SCD. Renowned medical institutions worldwide which have the state-of-the-art infrastructure and expertise to perform BMT and GT were outlined. The need for clinicians to make maximum effort to protect patients against graft versus host disease (GVHD) was reiterated. The transfer of this innovative medical technology will reduce the impact of SCD as a global public health problem. Evidenced-based public health approach was suggested to implement trait counselling research and conduct education to eliminate alleles of SCD.
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Medical Engineering and Informatics (IJMEI):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email subs@inderscience.com
Our Blog 
Follow us on Twitter 
Visit us on Facebook